Cardlytics filings document a Nasdaq-listed commerce media company's operating results, governance, capital structure, and material events. Form 8-K reports furnish quarterly and annual results, conference-call materials, cost-reduction actions, leadership and compensatory arrangements, and securities information for the company's common stock listed under CDLX.
The filing record also includes disclosure on the completed divestiture of Bridg, including the asset-sale closing and related unaudited pro forma financial statements. Proxy materials cover board matters, shareholder voting items, executive compensation, equity awards, and related governance disclosures for the company’s commerce media business.
Cardlytics, Inc. (CDLX) notice reports a proposed sale of 68,685 common shares through Fidelity Brokerage Services with an aggregate market value of $76,803.57, and an approximate sale date of 08/19/2025 on NASDAQ. The shares were acquired by restricted stock vesting from the issuer on 08/15/2025 and were issued as compensation. The filer disclosed two recent sales by Amit Gupta: 6,725 shares sold on 07/02/2025 for $11,987.99 and 68,260 shares sold on 08/18/2025 for $76,806.15. The notice includes the standard signature representation that the seller is not aware of undisclosed material adverse information.
Cardlytics, Inc. (CDLX) filed a Form 144 notice reporting a proposed sale of 68,260 common shares through Fidelity Brokerage Services with an aggregate market value of $76,806.15. The filing lists the number of shares outstanding as 53,236,901 and indicates an approximate sale date of 08/18/2025 on NASDAQ. The securities were acquired as restricted stock vesting from the issuer on 08/15/2025 and the payment nature is noted as compensation.
The filer also reported a prior sale on 07/02/2025 of 6,725 shares for gross proceeds of $11,987.99. The filing includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.
Cardlytics (CDLX) Chief Financial Officer Alexis DeSieno reported the vesting and partial disposition of restricted stock units. On 08/14/2025 Ms. DeSieno had 43,750 RSUs vest, which increased her beneficial ownership to 215,608 shares. The next day, 08/15/2025, she sold 26,048 shares at a weighted average price of $1.217 to satisfy tax withholding obligations, leaving her with 189,560 shares reported as directly beneficially owned. The RSU award referenced was originally for 350,000 shares, with 50% having vested on 08/14/2024 and the remainder vesting quarterly over the following year, subject to continued employment.
Form 144 filing for Cardlytics, Inc. (CDLX) shows a proposed sale of 26,048 common shares through Fidelity Brokerage Services on 08/15/2025 with an aggregate market value of $31,695.21. The shares were acquired on 08/14/2025 via restricted stock vesting and were paid as compensation. The filing lists total shares outstanding of 53,236,901. The filer also reported two prior sales in the past three months: 26,217 shares sold on 05/15/2025 for $50,808.55 and 7,324 shares sold on 07/02/2025 for $13,055.76. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.